Ruwanthi Kolamunnage-Dona

List of Publications by Year
in descending order

58 papers	2,066 citations	304743 22 h-index	254184 43 g-index
63 all docs	63 docs citations	63 times ranked	3676 citing authors

#	Article	IF	Citations
1	Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Medical Research Methodology, 2017, 17, 53.	3.1	503
2	Patients with epilepsy: Cognitively compromised before the start of antiepileptic drug treatment?. Epilepsia, 2010, 51, 48-56.	5.1	157
3	Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues. BMC Medical Research Methodology, 2016, 16, 117.	3.1	112
4	Assessment and clinical course of hypocalcemia in critical illness. Critical Care, 2013, 17, R106.	5.8	97
5	Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS ONE, 2016, 11, e0149803.	2.5	75
6	Joint modelling of longitudinal and competing risks data. Statistics in Medicine, 2008, 27, 6426-6438.	1.6	69
7	Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 301-308.	10.7	64
8	A review of the handling of missing longitudinal outcome data in clinical trials. Trials, 2014, 15, 237.	1.6	64
9	A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro-Oncology, 2020, 22, 278-289.	1.2	56
10	Assessing the potential for outcome reporting bias in a review: a tutorial. Trials, 2010, 11, 52.	1.6	54
11	Predicting Risk of Serious Bacterial Infections in Febrile Children in the Emergency Department. Pediatrics, 2017, 140, .	2.1	54
12	Enhanced relapse prevention for bipolar disorder by community mental health teams: cluster feasibility randomised trial. British Journal of Psychiatry, 2010, 196, 59-63.	2.8	52
13	Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. Journal of Infectious Diseases, 2018, 217, 1118-1127.	4.0	47
14	Pharmacodynamics of the Orotomides against *Aspergillus fumigatus* : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. MBio, 2017, 8, .	4.1	47
15	joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes. BMC Medical Research Methodology, 2018, 18, 50.	3.1	42
16	Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. Journal of Personalized Medicine, 2017, 7, 1.	2.5	41
17	Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study. PLoS ONE, 2014, 9, e106118.	2.5	39
18	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clinical Infectious Diseases, 2017, 64, 1557-1563.	5.8	39

#	Article	IF	Citations
19	Depressive and manic symptoms are not opposite poles in bipolar disorder. Acta Psychiatrica Scandinavica, 2011, 123, 206-210.	4.5	37
20	Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis. BMC Medical Research Methodology, 2016, 16, 168.	3.1	37
21	The influence of competing-risks setting on the choice of hypothesis test for treatment effect. Biostatistics, 2007, 8, 689-694.	1.5	34
22	Brief Interventions in Dependent Drinkers: A Comparative Prospective Analysis in Two Hospitals. Alcohol and Alcoholism, 2011, 46, 434-440.	1.6	26
23	Joint Models of Longitudinal and Time-to-Event Data with More Than One Event Time Outcome: A Review. International Journal of Biostatistics, 2018, 14, .	0.7	23
24	Bayesian joint modelling of longitudinal and time to event data: a methodological review. BMC Medical Research Methodology, 2020, 20, 94.	3.1	23
25	A Comparison of Joint Models for Longitudinal and Competing Risks Data, with Application to an Epilepsy Drug Randomized Controlled Trial. Journal of the Royal Statistical Society Series A: Statistics in Society, 2018, 181, 1105-1123.	1.1	22
26	Statistical primer: performing repeated-measures analysisâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 539-544.	1.1	19
27	Treatment Outcomes of Incidental Intracranial Meningiomas: Results from the IMPACT Cohort. World Neurosurgery, 2020, 138, e725-e735.	1.3	19
28	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technology Assessment, 2019, 23, 1-140.	2.8	18
29	Novel biomarker combination improves the diagnosis of serious bacterial infections in Malawian children. BMC Medical Genomics, 2012, 5, 13.	1.5	17
30	Cardiovascular drugs and COVIDâ€19 clinical outcomes: A living systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 4534-4545.	2.4	16
31	Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is Associated With Clostridium difficile Infection Recurrence: A Prospective Cohort Study. Clinical Infectious Diseases, 2014, 59, 1429-1436.	5.8	15
32	Faster Monte Carlo estimation of joint models for time-to-event and multivariate longitudinal data. Computational Statistics and Data Analysis, 2020, 151, 107010.	1.2	14
33	Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
34	Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 879-887.	3.7	12
35	A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC). BMC Public Health, 2011, 11, 528.	2.9	10
36	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 2062-2072.	5.8	10

#	Article	IF	Citations
37	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open, 2015, 5, e009566.	1.9	9
38	ECONOMIC EVALUATION OF NEBULIZED MAGNESIUM SULPHATE IN ACUTE SEVERE ASTHMA IN CHILDREN. International Journal of Technology Assessment in Health Care, 2014, 30, 354-360.	0.5	7
39	Cardiovascular drugs and COVID–19 clinical outcomes: a systematic review and meta–analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 3577-3599.	2.4	7
40	Is the Interleukin 8 Promoter Polymorphism rs4073/-251T >A Associated With Clostridium difficile Infection?. Clinical Infectious Diseases, 2014, 58, e148-e151.	5.8	6
41	Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study. Trials, 2016, 17, 222.	1.6	6
42	Time-dependent efficacy of longitudinal biomarker for clinical endpoint. Statistical Methods in Medical Research, 2018, 27, 1909-1924.	1.5	6
43	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	6
44	Procalcitonin, C-reactive protein, neutrophil gelatinase-associated lipocalin, resistin and the APTT waveform for the early diagnosis of serious bacterial infection and prediction of outcome in critically ill children. PLoS ONE, 2021, 16, e0246027.	2.5	6
45	External validation and recalibration of an incidental meningioma prognostic model – IMPACT: protocol for an international multicentre retrospective cohort study. BMJ Open, 2022, 12, e052705.	1.9	6
46	Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
47	Investigation of one–stage meta–analysis methods for joint longitudinal and time–to–event data through simulation and real data application. Statistics in Medicine, 2019, 38, 247-268.	1.6	5
48	Investigation of 2–stage meta–analysis methods for joint longitudinal and time–to–event data through simulation and real data application. Statistics in Medicine, 2018, 37, 1227-1244.	1.6	4
49	A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. Alcohol and Alcoholism, 2016, 51, 584-592.	1.6	3
50	A multistate modelling approach for pancreatic cancer development in genetically high-risk families. Journal of the Royal Statistical Society Series C: Applied Statistics, 2013, 62, 201-212.	1.0	2
51	Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. Journal of Personalized Medicine, 2017, 7, 19.	2.5	2
52	Spatial Linear Mixed Effects Modelling for OCT Images: SLME Model. Journal of Imaging, 2020, 6, 44.	3.0	2
53	Clinical studies of incidental intracranial meningiomas–towards high-quality evidence-based practice. Acta Neurochirurgica, 2020, 162, 673-674.	1.7	2
54	Spatial and spatio-temporal statistical analyses of retinal images: a review of methods and applications. BMJ Open Ophthalmology, 2020, 5, e000479.	1.6	1

#	Article	IF	Citations
55	Evaluating statistical characteristics of biomarker-guided trial designs. Trials, 2015, 16, .	1.6	0
56	MNGI-22. A PROGNOSTIC INDEX TO PREDICT THE RISK OF ACTIVE MONITORING FAILURE FOR INCIDENTALLY-FOUND ASYMPTOMATIC MENINGIOMAS. Neuro-Oncology, 2018, 20, vi153-vi153.	1.2	0
57	Adjustment for the measurement error in evaluating biomarker performances at baseline for future survival outcomes: Time-dependent receiver operating characteristic curve within a joint modelling framework. Research Methods in Medicine & Health Sciences, 2021, 2, 51-60.	1.2	0
58	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-168.	0.7	0